Bilayer and Multilayer Tablet for Combination Therapy

Fig. 1: Schematic representation of bilayer tablet (two layers) and multilayer tablet (multiple layers) showing layer names and their functions.

Source: Original schematic prepared for this review; conceptual basis supported by published bilayer-tablet literature [1,2].

4.2. RATIONALE FOR BILAYER TABLETS DESIGN

Splitting a tablet into a bilayer layout becomes incredibly valuable when two drugs call for different delivery speeds, or when you must prevent reactive ingredients from touching each other directly. For example, the first layer can be engineered to dissolve rapidly for an immediate therapeutic effect, while the second layer uses a water-loving (hydrophilic) or water-repelling (hydrophobic) matrix to stretch out drug delivery over hours. If chemical stability is a major threat, a middle placeholder or placebo layer can act as a protective wall. This technology also handles wide gaps in drug dosages and accommodates clashing processing demands effortlessly.

4.3 TYPES OF BILAYER SYSTEMS

5. MULTILAYER TABLETS

5.1 Definition and Structure

Multilayer tablets stack three or more functional zones on top of each other. These extra layers can hold a variety of different APIs, chemical blocks, release-modifying matrices, or outer shields. While adding more layers naturally introduces extra process variables and structural risks, it gives developers unparalleled freedom to orchestrate complex, multi-stage delivery timelines.

5.2 ADVANTAGES AND CONSTRAINTS OF MULTILAYER ARCHITECTURE

Multilayer designs excel at building timed dosing patterns, chaining multiple release profiles, and isolating chemically volatile ingredients that crash upon contact. The main drawback is the heavy spike in factory assembly trouble caused by multiple joint lines. As you stack more layers, controlling joint adhesion, individual layer weights, powder movement inside the machinery, compression pressure memories, and batch consistency becomes much tougher.

6. RATIONALE FOR COMBINATION THERAPY

Doctors opt for combination therapies when deploying multiple active ingredients can trigger synergistic effects, tap into complementary biological pathways, or offer superior disease management. Merging these medicines into a single fixed-dose combination (FDC) pill makes life much easier for patients, reducing daily pill burdens and boosting compliance. However, if you simply dump multiple APIs into a basic single-layer tablet, you often trigger severe formulation failures due to conflicting dosages, stability issues, poor compression traits, or clashing dissolution patterns.

7. FORMULATION STRATEGIES

7.1 Immediate- and Modified-Release Combination

A highly popular approach in layered design is loading one active drug into a fast-melting (immediate-release) zone and embedding the second drug into a slow-release (sustained or controlled-release) matrix. To slow things down, developers often turn to water-loving polymers like hydroxypropyl methylcellulose (HPMC) [30].

The moment this material meets digestive fluids, it hydrates rapidly to form a thick, protective gel wall. This gooey barrier steadily controls how fast the drug escapes, balancing both matrix erosion and molecular diffusion. On the flip side, water-repelling (hydrophobic) polymers can be mixed in to further choke off water entry and fine-tune the release speed. Meanwhile, the fast-acting layer is packed with aggressive disintegrants and fast-dissolving additives to guarantee a rapid therapeutic onset [31].

7.2 Separation of Incompatible APIs

Using a layered structure can effectively isolate two clashing active drugs, minimizing direct contact during factory compression or long-term shelf storage [1,7]. However, inserting a wall should never replace a thorough preformulation compatibility check. When mapping out drug-containing zones split by a middle barrier, developers must pick shielding materials based on the exact degradation pathways, moisture vulnerabilities, and expected chemical interactions. For instance, to block reactive triggers, boost product stability, and schedule sequential dosing, researchers recently utilized a smart core tablet wrapped in a middle barrier coat, finished off with an outer active drug film [4].

7.3 Fixed-Dose Combination Strategy

Bilayer fixed-dose combinations (FDCs) let formulators custom-build each section of a tablet to fit specific dosage volumes and release timelines while keeping everything in a single, user-friendly pill [22].

A prime example is a dual-matrix setup combining fast-dissolving glipizide with slow-release metformin hydrochloride [2]. Advanced development protocols frequently combine experimental designs (DoE), Raman tracking, thorough aging tests, and bioequivalence checks to successfully pair high-dose, long-acting drug bases with low-dose, fast-acting components [5,6].

7.4 Gastro-retentive and Site-Oriented Systems

To maximize drug absorption, layered tablets can be engineered to puff up or float, effectively locking them inside the stomach for extended periods. A classic application features a stomach-retained bilayer pill packing pantoprazole and clarithromycin, built using a balanced mix of sodium alginate, chitosan, and HPMC [3]. Engineering these specialized platforms requires extreme precision, as developers must meticulously test their structural endurance, floating buoyancy, gastric survival times, and shifting drug delivery tracks.

7.5 Release-Controlling and Barrier Layers

A functional layer does not always need an active drug to be useful. Purely inactive placeholders or barrier walls can easily control contact between separate drug zones, manipulate internal moisture levels, or dictate exactly when a compound gets exposed to body fluids. Naturally, the overall thickness, microscopic pore layout, material mix, and compression elasticity of these blank layers directly impact both the structural integrity of the joints and the final drug dissolution profiles.

8. MANUFACTURING APPROCHES

Industrial production typically starts by creating and processing each layer blend completely independently. If the raw ingredients possess good flow and compression traits, direct tableting can be used right away [29]. However, if the powders are difficult to handle, engineers turn to wet or dry granulation to upgrade their physical properties. The finished tablet is born by dropping these granular mixes into a single pressing die in a strict, step-by-step sequence before hitting them with a final compression stamp. The ultimate engineering battle in this workflow is creating a rock-solid inter-layer bond without over-compacting the granules, which can trigger trapped residual stress, alter pill porosity, or ruin the drug release curves [18].

8.1 Critical Process Parameters

Successfully running a multi-layer press requires strict control over individual layer weights, die fill depths, powder movement, pre-compression force, main compression pressure, turret rotation speeds, feeder calibration, machine lubrication, and punch dwell times. The exact weight of each factor shifts based on the machinery setup and raw material behaviors. Extensive compression studies show that operational speeds and pressing conditions directly dictate how well layers stick together, especially when touching formulas expand at different speeds when the pressure lets go [8,18].

8.2 Delamination and Layer Adhesion

Delamination occurs when the compressed layers of a tablet split apart right at their joint line [1].  This structural breakdown can happen unexpectedly during machine ejection, routine handling, automated packaging, or long-term storage [7].  A variety of factors drive this structural failure, including material warping, surface textures, trapped inner stress, extreme compaction force, punch dwell times, and manufacturing line speeds. When adjacent powder blends display vastly different elastic recovery profiles, they expand at unequal rates the moment the compression pressure releases. This physical mismatch triggers heavy mechanical stress across the boundary line, causing the layers to peel apart [19].

Fig. 2: Simplified representation of factors that can influence interfacial adhesion and delamination in layered tablets.

Source: Original schematic prepared for this review; mechanism and process-risk concepts supported by [2,3,16].

Engineers must evaluate the overall crushing strength of the tablet and its specific joint toughness (interfacial strength) as two completely separate metrics. It is highly common for a tablet to pass standard hardness tests with acceptable crushing scores while actually harboring a critically weak internal interface. To accurately map out the physical durability of these internal boundaries, researchers rely on specialized structural testing setups like diametral split tests, direct shear testing, or indentation-based mechanical trials [8,9].

9. EXCIPIENTS AND MATERIALS

When picking additives for a multi-layer tablet, formulators cannot just look at how each layer behaves on its own. They must deeply analyze how touching materials interact across the dividing line. Drastic shifts in particle elasticity, plasticity, brittleness, water absorption, and lubrication levels across layers directly dictate the final joint toughness and the mechanical survival of the pill.

10. CRITICAL QUALITY ATTRIBUTES AND EVALUATION

Testing a multi-layer tablet requires looking beyond standard quality checkpoints to analyze unique structural challenges introduced by the multi-tier design. On top of tracking classic parameters like visual appearance, overall weight, thickness, crushing hardness, and friability, quality control teams must rigorously evaluate individual layer weights, dosage uniformity across layers, interface bonding strength, and API-specific dissolution tracking [1,10].

Because different active ingredients in these setups are intentionally engineered to release at contrasting speeds, dissolution testing becomes highly complex [20]. Analytical methods must be sharp enough to quantify each separate drug independently without any molecular cross-interference. This is especially true for fixed-dose combinations where one component dissolves in minutes while the other slowly bleeds out over twelve hours. Standard hardness and friability tests often miss these critical interior defects, making specialized interface testing absolutely essential [8,9].

11. QUALITY BY DESIGN, RISK MANAGEMENT AND PROCESS ANALYTICAL TECHNOLOGY

Quality by Design (QbD) offers a highly organized blueprint that connects raw material traits, factory process settings, and measurable quality benchmarks directly to how the tablet performs in the real world[14]. When mapping out the Quality Target Product Profile (QTPP) for a multi-layer tablet, engineers must factor in the total number of layers, the exact clinical purpose of each tier, specific drug dosages, the planned delivery sequence, structural joint endurance, and chemical shelf-life.

Fig. 3: Simplified QbD framework for development and control of layered tablets.

Source: Original schematic prepared for this review; principles aligned with ICH Q8(R2), Q9(R1) and Q10 [22–24].

Critical Material Attributes (CMAs) like particle size distributions, powder flowability, compression mechanics, elasticity, and moisture levels must be balanced against Critical Process Parameters (CPPs) [18,33]. These manufacturing variables include die fill depths, pre-compression pressure, main punch force, turret speeds, machine dwell times, and lubrication rates.

Instead of tweaking one single formulation ingredient at a time, researchers rely on Design of Experiments (DoE) to study how raw material setups and machine settings cross-interact [33].  This multi-variable approach is incredibly helpful because final drug dissolution profiles, layer ingredient choices, and punch pressures are heavily dependent on each other. A great example of using QbD to perfect a multi-tier medicine is the high-dose sustained-release metformin and low-dose immediate-release evogliptin combination setup [5].

Deploying Process Analytical Technology (PAT) right on the manufacturing line delivers rich, real-time insights during scale-up. For instance, teams routinely use inline Raman spectroscopy to monitor layer characteristics during tablet compression. The ultimate commercial value of any PAT tool relies on its ability to track a critical quality trait instantly and support a validated, tight factory control strategy.

Quality risk management is uniquely vital for layered medicines because multi-tier systems trigger hidden failure modes rarely seen in standard single-layer production [15]. Subtle factory slip-ups can easily cause incorrect layer weights, powder separation inside the hopper, cross-batch contamination, critically weak layer boundaries, and unexpected shifts in drug release curves driven by punch pressure variations. Teams rely on structured risk ranking systems and Failure Mode and Effects Analysis (FMEA), aligned with ICH Q9(R1) guidelines, to prioritize and eliminate these production hazards before they occur [15,16].

12. REPRESENTATIVE APPLICATIONS IN COMBINATION THERAPY

13. RECENT ADVANCES  AND  EMERGING MANUFACTURING

Modern laboratory breakthroughs have pushed multi-layer engineering way beyond basic two-tier compression presses toward highly integrated formulation mechanics. When active drugs are completely incompatible and cannot touch, advanced multi-layer API coating setups offer an excellent alternative route. Teams utilize deep experimental designs (DoE) to uncover exactly how shifting coating chemistry impacts machine processing trails.

A great example of this evolution is the montelukast and levocetirizine combination design [4].  Instead of pushing powders in a die, this formulation uses a solid core tablet, seals it with an inactive protective barrier wall, and sprays a second drug-rich active coating on the outside. When chemical clashing is a major hurdle during development, this fluid-bed layering path shows how multi-tier design can step past traditional mechanical compression limits.

Next-generation additive manufacturing is another highly promising frontier. While industrial teams are experimenting with droplet deposition modeling and automated injection molding to customize the internal microstructures of layered medicines [23,24], dual-nozzle fused deposition modeling (FDM) 3D printing has emerged as a powerhouse for building custom bilayer pills[11,12].  Injection molding excel at forging ultra-dense tablet structures that guarantee smooth, long-term drug release tracks. On the flip side, droplet deposition prints let engineers manipulate microscopic pill porosity to trigger immediate, high-speed drug dissolution loops [25,26].

Fig. 4: Emerging manufacturing routes relevant to complex and personalized layered tablets.

Source: Original schematic prepared for this review; technologies discussed in [18,21].

14. ADVANTAGES AND LIMITATIONS

14.1 Advantages

• Combines multiple active ingredients or independent functional zones inside a single solid pill.
• Achieves completely different, tailored drug dissolution tracks within one manufacturing unit.
• Minimizes direct contact between clashing ingredients using customized placebo barrier walls or separation films.
• Allows independent optimization of drug dosages, excipient choices, and release speeds for every single layer.
• Accommodates timed, sequential, or site-specific drug delivery paths inside the digestive tract.
• Provides a highly versatile platform for building complex delivery schedules and robust fixed-dose combinations.
• Boosts patient convenience and daily compliance by dropping pill counts and cutting down dosage frequencies.

14.2 Limitations

• Sparks a massive spike in factory setup trouble compared to standard, single-layer tableting.
• Creates heavy delamination or interface cracking risks during machine ejection, transport, and shelf storage.
• Demands ultra-strict control loops over feeder powder flows and individual layer fill masses.
• Triggers particle segregation or cross-batch contamination when running mismatching blends on the same press.
• Faces intense interface bonding struggles due to contrasting material elasticity and compression profiles.
• Complicates standard factory scale-up trials, process validation steps, and routine in-line checks.
• Requires highly complex, multi-wavelength dissolution assays to quantify overlapping active drugs simultaneously.
• Increases initial development costs and manufacturing timelines due to specialized tooling and machinery setups.

15. Current Challenges and Future Perspectives

The ultimate test for layered pills is forcing multiple zones to do their unique jobs perfectly without letting the extra joint lines trigger structural defects on the factory floor. Instead of treating formulation steps, compression physics, joint adhesion, and final dissolution as separate hurdles, modern pharmaceutical science is shifting toward an all-inclusive approach. It is about studying how raw material physics, machine stress, and internal particle layouts cross-interact across the full life cycle of the medicine.

Frameworks like QbD, multi-variable experimental designs (DoE), and inline PAT monitoring provide a reliable blueprint to make industrial scale-up predictable and efficient. Advanced digital layering toolsets can take this a step further, letting formulators adjust dosages, geometry profiles, and dissolution tracks all inside a single unit. However, how quickly advanced routes like 3D printing or droplet deposition step into commercial factories depends on a few heavy factors: raw material stability, batch consistency, printing speeds, regulatory compliance pathways, and validation tracking.

Chemically isolated multi-tier tablets are incredibly promising for multi-drug treatments where active compounds fall apart if they touch. Ultimately, look beyond basic laboratory dissolution graphs—developers must rigorously track how these complex profiles hold up over multi-year aging tests and ensure the manufacturing loop remains simple. Proving these advanced systems outperform existing single-pill options in real clinical pharmacokinetic trials remains the biggest obstacle to widespread medical adoption.

16. DEVELOPMENT CONSIDERATIONS FOR LAYERED COMBINATION TABLETS

16.1 Compatibility Assessment Before Layer Selection

Formulators must uncover the exact chemical mechanisms driving drug clashing before choosing to physically split them into layers. Active ingredients and excipients can react in dozens of hidden ways, and simply stacking them will not stop moisture or volatile gases from traveling across layer zones. During preformulation screening, developers must carefully track thermal stability, moisture sensitivity, impurity generation, and assay drops when mixing drugs with proposed additives. If direct contact is the main issue, a physical barrier wall works beautifully. However, if ambient moisture or gas exchange is driving the degradation, environmental controls and protective packaging become just as critical as the tablet architecture.

16.2 Selection of Layer Architecture

Never choose the layout or count of tablet layers simply based on what your current factory line can handle easily. The decision must stem directly from the exact therapeutic performance required by the patient. If your therapy only calls for two distinct release speeds, a basic bilayer setup is perfect. If you must completely isolate two sensitive drug zones, a three-layer placeholder configuration is ideal. Complex sequential release tracks demand highly intricate multi-layer setups—but remember, every extra layer introduces a fresh boundary line prone to manufacturing defects. Formulators should screen multiple layer architectures right at the start and lock in the simplest possible design that hits the target profile.

16.3 Material and Mechanical Considerations

Powder characteristics dictate whether a layer joint holds together or fails. Particle shape distributions, moisture contents, bulk densities, and deformation behaviors govern how evenly a die fills and how much surface contact is forged under the punch face. Brittle excipients shatter under high pressure to create fresh, clean bonding surfaces, whereas plastic compounds warp and link closely. If two neighboring layers display mismatching elastic recovery profiles when the punch pressure lets go, severe internal stress forms right at the interface. Selecting additives is a balancing act—you must optimize how materials behave within their own zone and how they cross-bond with neighboring layers in the finished tablet.

16.4 Scale-Up and Manufacturing Control

Scaling up a layered tablet is far more complex than just making a massive batch of powder. Shifting turret speeds, powder feeder dynamics, die residence times, and compression history profiles heavily alter how layers form and stick together. The physical setup of an industrial press can radically modify powder flow loops. To transition to a commercial scale smoothly, engineers must establish wide operational windows for every key machine setting while proving the finished pill hits all quality benchmarks. Do not just rely on final product sorting—monitoring real-time punch pressures and layer weight trends during tableting lets you catch defects before they ruin a batch.

16.5 Dissolution Method Development for Multiple APIs

Testing a tablet that packs contrasting active ingredients designed to dissolve at completely different speeds requires advanced analytical layouts. The dissolution test must be sensitive enough to capture real-world shifts in how each layer behaves. Formulators frequently need specialized sample handling loops or separate detection wavelengths to map out overlapping curves without cross-interference. When building a new method, check that the chosen media volume and sampling intervals truly mirror the planned drug delivery tracks without masking subtle, critical flaws between layers.

16.6 Patient-Centred Value of Layered Dosage Forms

The true clinical value of a multi-layer tablet relies entirely on what real-world problem it solves for the patient. A well-designed pill can deliver a medicine at multiple speeds so people do not have to disrupt their day for repeated doses, or pack separate therapies into a single unit to ease swallow burdens. Never assume a complex tablet automatically boosts patient compliance. During the initial design phase, formulators should walk through practical user details: daily dosing schedules, the clarity of the instructions, physical tablet sizes for easy swallowing, and whether it makes therapeutic sense to link those specific drugs together.

17. RESEARCH GAPS AND OPPORTUNITY

Despite the flood of advanced engineering concepts in modern literature, standardized testing protocols are still missing. Different research groups utilize completely unique testing rigs to track interface bonding strength, making it incredibly difficult to compare data across studies. Furthermore, the vast majority of published work remains confined to small laboratory settings—papers routinely showcase flawless dissolution charts but skip over process scalability, machine repeatability, or long-term manufacturing viability.We need deep comparative studies that track how material physics, compaction history, and joint layouts cross-interact across diverse tableting platforms. There is a massive opportunity to advance the field by linking real-time factory process analytical tools (PAT) with multi-variable experimental setups and deep mechanical compaction profiles.

Inline monitoring of layer masses, punch forces, and powder behaviors can spot structural flaws early before they turn into batch rejections.Advanced additive manufacturing offers unparalleled geometric freedom, but developers cannot celebrate design flexibility without locking down tight quality loops. You need reliable controls to guarantee every single printed pill hits the correct dosage, maintains long-term stability, and scales up efficiently. The field will progress rapidly when formulation science, industrial engineering, advanced analytical chemistry, and regulatory quality frameworks are merged into a unified development loop.

Connecting how a tablet performs in a lab to what patients actually need in daily life is another wide-open opportunity. Layered setups are typically engineered to match a target laboratory dissolution line, but the real impact relies on internal pharmacokinetics, clinical therapeutic windows, and how well the dosing layout fits into a patient’s routine. Instead of just proving a machine can compress multiple release patterns, the focus must shift to identifying when a layered setup delivers a meaningful, proven advantage for drug delivery and patient therapy.

18. PRACTICAL POINTS FOR FORMULATION STUDENTS

For a pharmaceutics student, the core logic behind bilayer or multilayer tablets is straightforward: different sections of a single tablet are assigned unique therapeutic jobs. One zone can throw out a drug immediately, a second zone acts as a slow-release matrix, and a middle layer can sit between them to separate clashing ingredients. This complex layout is only worth choosing if keeping things separate works significantly better than simply blending all components into a standard single-layer tablet.                  

When evaluating a new formulation, four simple questions will help guide your design pathway: Do the active drugs coexist safely or do they clash chemically? Do they need to dissolve at the same speed or completely separate paces? Can both blends be compressed using the exact same machine configuration? Do you actually need a physical barrier? Your answers here will point you toward a standard pill, a basic bilayer, or a complex multilayer design.

On the practical side, students should focus on four foundational quality targets: ensuring every independent layer maintains the exact right weight and uniform drug dose, keeping the layer interfaces tightly bonded so they never split, making sure each active drug dissolves exactly as planned, and confirming the tablet resists chemical degradation while sitting on the shelf.